The impressive optoelectronic performance and low production cost of metal halide perovskites have inspired applications well beyond efficient so-lar cells. Herein, we widen the materials engineer-ing options available for the efficient and selective photocatalytic oxidation of benzylic alcohols - an industrially significant reaction - using forma-midinium lead bromide (FAPbBr3) and other per-ovskite based materials. The best performance was obtained using a FAPbBr3/TiO2 hybrid photocata-lyst under simulated solar illumination. Detailed optical studies reveal the synergetic photophysical pathways arising in FAPbBr3/TiO2 composites. An experimentally supported model rationalizing the large conversion enhancement over the pure con-stituents shows that this strategy offers new pro-spects for metal halide perovskites in photocatalyt-ic application.

Inspired by the efficient perovskite solar cells, we developed a three-component hybrid perovskite-based solar photocatalyst cell - NiO_x/FAPbBr₃/TiO₂ - for C(sp³)-H bonds activation with high selectivity (~90%) and high conversion rates (3800 µmol g^-1 h^-1) under ambient conditions. Time-resolved spectroscopy on our photocatalytic cell reveals efficient exciton dissociation and charge separation, where TiO₂ and NiO_x serve respectively as the electron and hole transporting layers. The photo-generated charge carriers, injected into TiO₂ and NiO_x, drive the challenging C-H activation reaction via the synergetic effects of their band alignment relative to FAPbBr₃. The reaction pathway is investigated by controlling the free radical formation and we find that C-H activation is mainly triggered by hole oxidation. Besides aromatic alkanes, also C(sp³)-H bond in cycloalkanes can selectively be oxidised. This work demonstrates a generic strategy for engineering high-performance photocatalysts based on the perovskite solar cell concept.

Metastasis is the primary cause of colorectal cancer (CRC) death. The liver and lung, besides adjacent lymph nodes, are the most common sites of metastasis. Here, we aimed to study the lymph nodes, liver, and lung CRC metastasis by quantitative spatial proteomics analysis using CRC cell-based models that recapitulate these metastases. The isogenic KM12 cell system composed of the non-metastatic KM12C cells, liver metastatic KM12SM cells, and liver and lung metastatic KM12L4a cells, and the isogenic non-metastatic SW480 and lymph nodes metastatic SW620 cells, were used. Cells were fractionated to study by proteomics five subcellular fractions corresponding to cytoplasm, membrane, nucleus, chromatin-bound proteins, and cytoskeletal proteins, and the secretome. Trypsin digested extracts were labeled with TMT 11-plex and fractionated prior to proteomics analysis on a Q Exactive. We provide data on protein abundance and localization of 4710 proteins in their different subcellular fractions, depicting dysregulation of proteins in abundance and/or localization in the most common sites of CRC metastasis. After bioinformatics, alterations in abundance and localization for selected proteins from diverse subcellular localizations were validated via WB, IF, IHC, and ELISA using CRC cells, patient tissues, and plasma samples. Results supported the relevance of the proteomics results in an actual CRC scenario. It was particularly relevant that the measurement of GLG1 in plasma showed diagnostic ability of advanced stages of the disease, and that the mislocalization of MUC5AC and BAIAP2 in the nucleus and membrane, respectively, was significantly associated with poor prognosis of CRC patients. Our results demonstrate that the analysis of cell extracts dilutes protein alterations in abundance in specific localizations that might only be observed studying specific subcellular fractions, as here observed for BAIAP2, GLG1, PHYHIPL, TNFRSF10A, or CDKN2AIP, which are interesting proteins that should be further analyzed in CRC metastasis.